IMR Press / EJGO / Volume 41 / Issue 3 / DOI: 10.31083/j.ejgo.2020.03.5102
Open Access Original Research
The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer
Show Less
1 Departments of Obstetrics and Gynecology, National Defense Medical College Hospital, Saitama, Tokorozawa, Japan
2 Departments of Clinical Oncology, National Defense Medical College Hospital, Saitama, Tokorozawa, Japan
Eur. J. Gynaecol. Oncol. 2020, 41(3), 386–390; https://doi.org/10.31083/j.ejgo.2020.03.5102
Submitted: 14 December 2018 | Accepted: 14 February 2019 | Published: 15 June 2020
Abstract

urpose: This study evaluated the appropriate number of cycles of neoadjuvant chemotherapy (NAC) before interval debulking surgery (IDS) in advanced ovarian cancer. Materials and Methods: Cases with advanced ovarian cancer who received a combination of taxane and platinum as NAC and IDS at this institution between 2001 to 2016 were identified. The cases were divided into two groups; patients who received six or four scheduled cycles of NAC (groups A and B, respectively). Results: Thirty-six cases were in group A and 35 cases in group B. Progression-free survival (PFS) and overall survival (OS) in group A were better than those in group B (p = 0.01, < 0.01). In multivariate analysis, six scheduled cycles of NAC was an independent better prognostic factor for PFS (hazard ratio (HR), 0.56, p = 0.04) and OS (HR, 0.39; p = 0.01). Conclusion: In advanced ovarian cancer, six scheduled cycles of NAC demonstrated a better prognosis.

Keywords
Ovarian carcinoma
Neoadjuvant chemotherapy
Primary debulking surgery
Interval debulking surgery
Figures
Figure 1.
Share
Back to top